Zhou, Xin <br/><br/>
Real-world outcome and healthcare costs of relapsed or refractory multiple myeloma: A retrospective analysis from the Chinese experience.  [electronic resource] 

 -  Hematology (Amsterdam, Netherlands)  Jun 2016 
 - 280-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1607-8454 
<br/><br/><label>Standard No.: </label>10.1080/10245332.2015.1122259  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Asian People<br/>Bortezomib--administration & dosage<br/>China<br/>Costs and Cost Analysis<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Retrospective Studies<br/>Survival Rate